Cystic fibrosis–related diabetes in children: An update

Roy J. Kim

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Cystic fibrosis–related diabetes mellitus (CFRD) is the most common endocrine complication of cystic fibrosis (CF), affecting more than 50% of patients by the 4th decade of life. CFRD is often preceded by worsening pulmonary status and nutritional decline. Treatment of CFRD is associated with improvements in body weight and pulmonary function and a reduction in pulmonary exacerbations. Because of the clinical significance of CFRD, diabetes screening with an oral glucose tolerance test (OGTT) is recommended annually for all patients with CF starting at age 10 years. The OGTT detects CFRD with greater sensitivity than random glucose or hemoglobin A1c testing. The first-line treatment for CFRD is insulin. The use of other treatments such as oral medications remains under study.

Original languageEnglish (US)
Pages (from-to)e321-e326
JournalPediatric Annals
Volume45
Issue number9
DOIs
StatePublished - Sep 1 2016

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Cystic fibrosis–related diabetes in children: An update'. Together they form a unique fingerprint.

  • Cite this